|
|
Vaccine Detail
|
Recombinant Vaccinia-Mgp100 Vaccine |
| Vaccine Information |
- Vaccine Name: Recombinant Vaccinia-Mgp100 Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007104
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: gp100
- gp100 (PMEL)
gene engineering:
- Preparation: The gp100 sequences were inserted into the Bam HI J region of the fowlpox virus genome under the control of the vaccinia 40K promoter (Rosenberg et al., 2003).
- Description: This is for Melanoma Cancer. A recombinant vaccinia virus encoding a modified peptide of the gp100 melanoma-melanocyte antigen with potential use in cancer immunotherapy. gp100 human antigen is a wild type self-antigen expressed by melanocytes, pigmented retinal cells and most melanomas. This recombinant vaccinia Mgp100 encodes a fragment epitope of gp100 bearing 2 amino acids substitution; T->M at position 210 and 288 A ->V at position 210. This modification may stimulate tumor infiltrating lymphocytes (TIL) more efficiently (NCIT_C51978).
|
| Host Response |
|
|
| References |
NCIT_C51978: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C51978]
Rosenberg et al., 2003: Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Topalian SL, Sherry RM, Restifo NP, Wunderlich JR, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, Gritz L, Panicali DL, White DE. Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003; 9(8); 2973-2980. [PubMed: 12912944].
|
|
